AlphaWire

newswire

Stifel cuts Alnylam price target to $318, maintains buy rating

2026-07-31·newswire-us-stock-180146
Stifel cuts Alnylam price target to $318, maintains buy rating.

Investment firm Stifel recently lowered its price target for biopharmaceutical company Alnylam Pharmaceuticals to $318 from $444 while maintaining a buy rating. The cut came as Alnylam reported its second-quarter 2026 results. The company's shares fell 28.31% on July 30 to close at $205.48, after touching a 52-week low of $197.81 during the session.

The stock's 52-week range is $197.81 to $495.55. Alnylam, a biopharmaceutical company focused on RNA interference technology, reported approximately $3.714 billion in total revenue for 2025, including about $2.987 billion in net product revenue, up 81% from the previous year.

Based on the latest share price, the company's market capitalization is approximately $27.4 billion to $27.5 billion. Analysts broadly continue to rate the stock a buy, with an average price target of about $412.54. Stifel's $318 target is below the market average but still implies potential upside.

#Stocks #Earnings

Full text

Stifel cuts Alnylam price target to $318, maintains buy rating

Investment firm Stifel recently lowered its price target for biopharmaceutical company Alnylam Pharmaceuticals to $318 from $444 while maintaining a buy rating. The cut came as Alnylam reported its second-quarter 2026 results. The company's shares fell 28.31% on July 30 to close at $205.48, after touching a 52-week low of $197.81 during the session. The stock's 52-week range is $197.81 to $495.55. Alnylam, a biopharmaceutical company focused on RNA interference technology, reported approximately $3.714 billion in total revenue for 2025, including about $2.987 billion in net product revenue, up 81% from the previous year. Based on the latest share price, the company's market capitalization is approximately $27.4 billion to $27.5 billion. Analysts broadly continue to rate the stock a buy, with an average price target of about $412.54. Stifel's $318 target is below the market average but still implies potential upside.

Investment firm Stifel recently lowered its price target for biopharmaceutical company Alnylam Pharmaceuticals to $318 from $444 while maintaining a buy rating.

The cut came as Alnylam reported its second-quarter 2026 results. The company's shares fell 28.31% on July 30 to close at $205.48, after touching a 52-week low of $197.81 during the session. The stock's 52-week range is $197.81 to $495.55.

Alnylam, a biopharmaceutical company focused on RNA interference technology, reported approximately $3.714 billion in total revenue for 2025, including about $2.987 billion in net product revenue, up 81% from the previous year. Based on the latest share price, the company's market capitalization is approximately $27.4 billion to $27.5 billion.

Analysts broadly continue to rate the stock a buy, with an average price target of about $412.54. Stifel's $318 target is below the market average but still implies potential upside.

← Back to archive